Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12

S Selina Troester T Thomas Eder N Nadja Wukowits M Martin Piontek P Pablo Fernandez-Pernas J Johannes Schmoellerl B Ben Haladik G Gabriele Manhart M Melanie Allram M Margarita Maurer-Granofszky N Nastassja Scheidegger K Karin Nebral G Giulio Superti-Furga R Roland Meisel (Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany) B Beat Bornhauser P Peter Valent M Michael N. Dworzak J Johannes Zuber K Kaan Boztug F Florian Grebien

Abstract

Abstract Nucleoporin 98 (NUP98) fusion oncoproteins are strong drivers of pediatric acute myeloid leukemia (AML) with poor prognosis. Here we show that NUP98 fusion-expressing AML harbors an epigenetic signature that is characterized by increased accessibility of hematopoietic stem cell genes and enrichment of activating histone marks. We employ an AML model for ligand-induced degradation of the NUP98::KDM5A fusion oncoprotein to identify epigenetic programs and transcriptional targets that are directly regulated by NUP98::KDM5A through CUT&Tag and nascent RNA-seq. Orthogonal genome-wide CRISPR/Cas9 screening identifies 12 direct NUP98::KDM5A target genes, which are essential for AML cell growth. Among these, we validate cyclin-dependent kinase 12 (CDK12) as a druggable vulnerability in NUP98::KDM5A-expressing AML. In line with its role in the transcription of DNA damage repair genes, small-molecule-mediated CDK12 inactivation causes increased DNA damage, leading to AML cell death. Altogether, we show that NUP98::KDM5A directly regulates a core set of essential target genes and reveal CDK12 as an actionable vulnerability in AML with oncogenic NUP98 fusions.

Article Details

Volume / Issue Vol. 16, Issue 1
Published May 19, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (20)

S

Selina Troester

T

Thomas Eder

N

Nadja Wukowits

M

Martin Piontek

P

Pablo Fernandez-Pernas

J

Johannes Schmoellerl

B

Ben Haladik

G

Gabriele Manhart

M

Melanie Allram

M

Margarita Maurer-Granofszky

N

Nastassja Scheidegger

K

Karin Nebral

G

Giulio Superti-Furga

R

Roland Meisel

Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

B

Beat Bornhauser

P

Peter Valent

M

Michael N. Dworzak

J

Johannes Zuber

K

Kaan Boztug

F

Florian Grebien